Fluorinated tracers for imaging cancer with positron emission tomography

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 8, 2004, Pages 1182-1206

  Couturier, Olivier ^a   Luxen, André ^b   Chatal, Jean François ^a   Vuillez, Jean Philippe ^c   Rigo, Pierre ^d   Hustinx, Roland ^e  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Division of Nuclear Medicine   (France)

^d CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer imaging; Fluorinated tracers; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 FLUOROTYROSINE F 18; 3 FLUORO ALPHA METHYLTYROSINE F 18; 3' FLUOROTHYMIDINE; AMINO ACID; AMINO ACID DERIVATIVE; BROMIDE; CARRIER PROTEIN; CHOLINE DERIVATIVE; DNA; ESTRADIOL DERIVATIVE; ETANIDAZOLE; FLUORIDE SODIUM; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F 18; FLUOROOCTREOTIDE F 18; FLUOROURACIL; GLUCOSE; GLUCOSE TRANSPORTER; HEXOKINASE; IODINE 124; MISONIDAZOLE; MITOMYCIN C; NEUROTRANSMITTER; O (2 FLUOROETHYL)TYROSINE F 18; PENTOSE; TESTOSTERONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID METABOLISM; CANCER; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CYCLOTRON; DRUG METABOLISM; DRUG UPTAKE; FLOW CYTOMETRY; FLUORINATION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LIPID METABOLISM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN SYNTHESIS; REVIEW;

EID: 3943110318     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1607-9     Document Type: Review

References (299)

1. Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med 2002;32:2-5.
2. Warburg O. The metabolism of tumors. ; 1930. p. 75-327.
3. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14.
4. Schirrmeister H, Kuhn H, Guhlmann A, et al. Immunostaging in pancreatic cancer and chronic active pancreatitis: does in vivo FDG-uptake correlate with proliferative activity? J Nucl Med 2001;42:721-5.
5. Kubota R, Kubota K, Yamada S, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
6. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36:1854-61.
7. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D- glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9.
8. Lewis P, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-9.
9. Minn H, Clavo AC, Grenman R, et al. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995;36:252-8.
10. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90.
11. Johnstone RM, Scholefield PG. Amino acid transport in tumor cells. Adv Cancer Res 1965;9:143-226.
12. Isselbacher KJ. Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med 1972;286:929-33.
13. Bush H, Davis JR, Honig GR, et al. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 1959; 19:1030-9.
14. Wiseman G, Ghadially FN. Studies in amino-acid uptake by RD3 sarcoma cell suspensions in vitro. Br J Cancer 1955; 9:480.
15. Saier MH, Daniels GA, Boerner P, et al. Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth. J Membr Biol 1988;104:1-20.
16. Souba WW, Pacitti AJ. How amino acids get into cells: mechanisms, models, menus and mediators. J Parenter Enteral Nutr 1992;16:569-78.
17. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993;34:1936-43.
18. 18F-fluorodeoxyglucose in prolactinomas in relation to bromo-cryptine treatment. Eur J Nucl Med 1991;18:453-60.
19. Miyagawa G, Oku T, Uehara H, et al. Facilitated amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500-9.
20. Martarello L, McConathy J, Camp M, et al. Synthesis and biological evaluation of Syn and Anti FMACBC, new amino acids for tumor imaging with PET. J Label Compd Radiopharm 2001;44:S385-7.
21. 18F] 1-amino-3-fluorocyclobutane-l-carboxylic acid to image brain tumours. J Nucl Med 1999;40:331-8.
22. Uehara H, Miyagawa T, Tjuvajev J, et al. Imaging experimental brain tumors with 1-aminocyclopentane carboxylic acid and alpha-aminoisobutyric acid: comparison to fluorodeoxyglucose and diethylenetriaminepentaacetic acid in morphologically defined tumor regions. J Cereb Blood Flow Metab 1997;17:1239-53.
23. Kubota K, Yamada K, Yoshioka S, et al. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992; 17:361-3.
24. 11C]methionine. Jpn J Cancer Res 1989; 80:778-82.
25. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995;36:484-92.
26. 11C]- tyrosine imaging of soft-tissue tumors before and after therapy. J Nucl Med 1999;40:381-6.
27. Kuwert T, Morgenroth C, Woesler B, et al. Uptake of iodine-123-alpha- methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996;23:1345-53.
28. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Radiat Appl Instrum B 1992;19:227-37.
29. 18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 1989;30:1367-72.
30. 18F]fluoro-L-tyrosine by catalytic phase-transfer alkylation. J Label Compd Radiopharm 2001;44:S857-9.
31. 18F)fluorotyrosine [see comments]. J Nucl Med 1991; 32:1338-46.
32. Saier MH Jr. A functional-phylogenetic system for the classification of transport proteins. J Cell Biochem 1999; Suppl 33-34:84-94.
33. 11C-labelled amino acids in Walker 256 carcinosarcoma- bearing rats. Int J Rad Appl Instrum B 1991;18:197-204.
34. 18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 1993;20:895-9.
35. 18F-FDG. J Nucl Med 2003; 44:533-9.
36. 18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun 1997; 18:169-75.
37. Amano S, Inoue T, Tomiyoshi K, et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med 1998;39:1424-7.
38. 18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998;39:663-7.
39. 123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids [see comments]. J Nucl Med 1991; 32:1225-9.
40. 125I]iodo-L-tyrosine into U266 human myeloma cells: evidence for system T transport. Nucl Med Biol 2001;28:129-34.
41. 123I-Iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study. J Nucl Med 2002;43:1201-6.
42. Lahoutte T, Mertens J, Caveliers V, et al. Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain. J Nucl Med 2003;44:1489-94.
43. Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000;27:1509-17.
44. 131I scan. J Nucl Med 2001;42:71-6.
45. Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2- deoxy-D-glucose. Radiology 1996; 200:243-7.
46. Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 2001; 220:54-62.
47. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205-12.
48. 18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999;40:1367-73.
49. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058-65.
50. 18F]fluoroethyl)-L- tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med 2002; 29:1039-46.
51. Schreckenberger M, Kadalie C, Enk A, et al. First results of F-18-fluoroethyl-tyrosine PET for imaging of metastatic malignant melanoma. J Nucl Med 2001;42:30P.
52. 11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9.
53. Ishiwata K, Ido T, Takahashi T, et al. Feasibility study of fluorine-18 labeled dopa for melanoma imaging. Int J Rad Appl Instrum B 1989;16:371-4.
54. 18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A 1990;41:275-81.
55. 18F]- fluorodopa uptake for melanogenesis in murine metastatic melanomas. J Nucl Med 1991;32:95-101.
56. 3H-thymidine. Br J Cancer 1992;66:614-8.
57. 15O-water using compartment and noncompartment analysis. J Nucl Med 2001; 42:248-56.
58. 18F-FDG-FDOPA tumor imaging for assessing response to therapy. J Nucl Med 2001;42:257-8.
59. 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80.
60. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
61. 11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561-7.
62. 18F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 2003;30:1266-9.
63. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33:652-8.
64. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
65. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 1994; 733:416-24.
66. Reubi JC, Krenning EP, Lamberts SWJ, et al. In vitro detection of somatostatin receptors in human tumours. Metabolism 1992;41(9):104-10.
67. Reubi JC, Laissue J, Krenning EP, et al. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implication. J Steroid Biochem Mol Biol 1992;43:27-35.
68. Pearse AGE, Polak JM, Health CM. Polypeptide hormone production by carcinoid apudomas and their relevant cytochemistry. Virchows Arch [B] 1974;16:95-109.
69. Reubi JC, Maurer R, Klijn JG, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 1986;63:433-8.
70. Reubi JC, Lang W, Maurer R, et al. Distribution and biochemical characterization of somatostatin receptors in tumours of the human central nervous system. Cancer Res 1987; 47:5758-65.
71. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-17.
72. Reubi JC, Waser B, Sheppard M, et al. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF receptors. Int J Cancer 1990;45:269-74.
73. Reubi JC, Waser B, Vanhagen M, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992;50:895-900.
74. Reubi JC, Horisberger U, Waser B, et al. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207-14.
75. Goldshmith SJ, Macapinlac HA, O'Brien JP. Somatostatin receptor imaging in lymphoma. Semin Nucl Med 1995; 25:262-71.
76. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
77. Kvols LK, Reubi J-C, Horisberger U, et al. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts reponsiveness to octreotide. Yale J Biol Med 1992;65:505-18.
78. Bakker WH, Krenning EP, Breeman WAP, et al. Receptor scintigraphy with radioiodined somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals. J Nucl Med 1990;31:1501-9.
79. 111In-DTPA-D-Phe1l- octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-91.
80. 99mTc[N4-(D)-Phe1]octreotide, a new derivative with high affinity for somatostatin receptors. In: Nicolini M, Bandoli G, Mazzi U, editors. Technetium and rhenium in chemistry and nuclear medicine. New York: Cortina International, Raven; 1995. p. 395-400.
81. Maina T, Stolz B, Albert R, et al. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SZ 219-387) labelled with technetium 99m. Eur J Nucl Med 1994;21:437-44.
82. 111In-DTPA- octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003;44:708-16.
83. Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocr Rev 1991;12:450-82.
84. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumours. J Nucl Med 2001;42:213-21.
85. Ugur O, Kothari PJ, Finn RD, et al. Ga-66 labelled somatostatin analogue DOTA-D-Phe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumours. Nucl Med Biol 2002;29:147-57.
86. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-7.
87. 86Y-DOTA(O)-D-Phe(1)- Tyr(3)-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-8.
88. 18F]fluoropropionyl-D- Phe1-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 1994;21:819-25.
89. 86Y-DTPA-octreotide. Nucl Med Biol 1997;24:275-86.
90. Schottelius M, Wester HJ, Reubi JC, et al. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem 2002;13:1021-30.
91. Wester HJ, Schottelius M, Scheidhauer K, et al. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002;29:28-38.
92. 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117-22.
93. Kong X, Zhu Q, Vidal P, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992;36:808-18.
94. 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. J Fluorine Chem 1991;55:283-9.
95. 18F]fluoro-3′-deoxynucleosides. J Label Compd Radiopharm 1997;10:60-2.
96. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000;27:143-56.
97. 18F]FLT). J Radioanal Nucl Chem 2000;243:843-6.
98. 18F] fluoro-thymidine with 2,3′-O-anhydro-5′-O-(4,4′-dimethoxytrityl)thymidine. J Label Compd Radiopharm 2000;43:1211-8.
99. 18F labeling of 3-Boc-1-(2-deoxy-3-O-nosyl-5-O-trityl-b-D- lyxofuranosyl)thymine and other thymine derivatives. J Nucl Med 2000;41:255P.
100. 18F]FLT. Nucl Med Biol 2002;29:263-73.
101. Belt J, Marina N, Phelps D, et al. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 1993; 33:235-52.
102. Coppock D, Pardee A. Control of thymidine kinase mRNA during the cell cycle. Mol Cell Biol 1987;7:2925-32.
103. Gross M, Merrill G. Regulation of thymidine kinase protein levels during myogenic withdrawal from the cell cycle is independent of mRNA regulation. Nucl Acids Res 1988; 16:11625-43.
104. Sherley J, Kelly T. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8.
105. Ito M, Conrad S. Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. J Biol Chem 1990;265:6954-60.
106. Bartrek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996;8:805-14.
107. Ewen M. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 1994;13:45-66.
108. Sherr CD. Type cyclins. Trends Biol Sci 1995;20:187-90.
109. Sherr C, Roberts J. Inhibitors of mammalian G1 cycline-dependent kinases. Genes Dev 1995;9:1149-63.
110. Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
111. Hengstschlager M, Knofler M, Mullner E, et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 1994;269:13836-42.
112. Hengstschlager M, Oliver P, Hengstshlager-Ottnad E, et al. Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism. DNA Cell Biol 1996;15:41-51.
113. Hengstschlager M, Hengstshlager-Ottnad E, Oliver P, et al. The role of p16 in the E2F-dependent thymidine kinase regulation. Oncogene 1996;12:1635-43.
114. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7.
115. Shields A, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
116. Eriksson S, Kierdaszuk B, Mucnh-Peterson B, et al. Comparison of the substate specificities of human thymidiine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991;176:586-92.
117. Nottebrock H, Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol 1977;26:2175-9.
118. 18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imaging 2002;29:165-9.
119. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63:2681-7.
120. 18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29:1174-81.
121. 18F- fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003;44:1482-8.
122. 18]fluorothymidine-positron emission tomography for non-invasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
123. 18F-FDG. J Nucl Med 2003;44:1426-31.
124. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003;30:1407-12.
125. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.
126. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-6.
127. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
128. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9.
129. Shields AF, Dohmen BM, Mangner TJ, et al. Use of F-18FLT for imaging gastrointestinal tumors. J Nucl Med 2001; 42:108.
130. Carter EA, McKuster K, Syed S, et al. Comparison of (FLT)-F-18 with (18)FDG for differentiation between tumor and focal sites of infection in rats. J Nucl Med 2002; 43:1074.
131. Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525-34.
132. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87:516-24.
133. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001;42:1815-6.
134. 11C)choline. J Nucl Med 1997; 38(Suppl):250P.
135. 11C]choline. J Nucl Med 1997;38:842-7.
136. 11C-choline PET. J Nucl Med 2000;41:1507-13.
137. 18F- fluorodeoxyglucose. Cancer 1999;1999:1638-48.
138. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5.
139. Hara T, Yuasa M. Automated synthesis of fluorine-18 labeled choline analog: 2-fluoroethyl-dimethyl-2-oxyethylammonium. J Nucl Med 1997;38(Suppl):44P.
140. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2000;61:110-7.
141. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14.
142. 18F-fluorocholine. J Nucl Med 2002;43:92-6.
143. 18F]fluoro-D- glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002;4:267-73.
144. 18F- fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43:187-99.
145. 18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-80.
146. Yorek MA, Dunlap JA, Spector AA, et al. Effect of ethanolamine on choline uptake and incorporation into phosphatidylcholine in human Y79 retinoblatoma cells. J Lipid Res 1986;27:1205-13.
147. Rosen MA, Jones RM, Yano Y, et al. Carbon-11 choline: synthesis, purification, and brain uptake inhibition by 2-dimethylaminoethanol. J Nucl Med 1985;26:1424-8.
148. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004;31:312-6.
149. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984;25:1212-21.
150. 18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 1999;26:123-30.
151. Brandes SJ, Katzenellenbogen JA. Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol Pharmacol 1987;32:391-403.
152. Liu A, Carlson KE, Katzenellenbogen JA. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem 1992;35:2113-29.
153. Noé G, Cheng YC, Dabiké M, et al. Tissue uptake of human sex hormone-binding globuline an its influence on ligand kinetics in the adult female rat. Biol Reprod 1992;47:970-6.
154. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002; 67:765-75.
155. 18F]fluoroestradiol for breast cancer imaging. Nucl Med Biol 1999;26:473-9.
156. 18F]fluoro)-17 β-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum B 1987;14(1):15-25.
157. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-fluoroestradiol (FES). Nucl Med Biol 1997; 24:341-8.
158. 18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999;26:905-13.
159. Pomper MG, VanBrocklin H, Thieme AM, et al. 11β-Methoxy-, 11β-ethyl- and 17α-ethynyl-substitued 16α-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem 1990; 33:3143-55.
160. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-8.
161. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-74.
162. 18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. Nucl Med Biol 1993;20:735-45.
163. 18F] fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32:1526-31.
164. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998;28:290-302.
165. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-6.
166. 18F]fluoroestradiol-3,17β-disulphamate. Appl Radiat Isot 2001;55:631-9.
167. Lim JL, Zheng L, Berridge MS, et al. The use of 3-methoxymethyl-16β, 17β-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16α-fluoroestradiol. Nucl Med Biol 1996;23:911-5.
168. Rodig H, Brust P, Romer J, et al. Distribution of estrone sulfatase in
169. 18F]fluoro-estradiol-3,17β-disulfamate in rats, tumour-bearing mice and piglets. Appl Radiat Isot 2002;57:687-95.
170. 18F] fluoro-16 α-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography. J Med Chem 1988;31:1360-3.
171. 18F]fluoro-16 α-methyl-19- norprogesterone) for imaging progesterone receptor positive tumours with positron emission tomography. Cancer Lett 1991;59:125-32.
172. 18F]fluoro-16 α-methyl-19- norprogesterone) for imaging progesterone receptor positive tumours with positron emission tomography. Cancer Lett 1991;59:125-32.
173. 18F] fluoro-16 α-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography. J Med Chem 1988;31:1360-3.
174. Verhagen A, Elsinga PH, de Groot TJ, et al. A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography. Cancer Res 1991;51:1930-3.
175. 18F]fluoro-16 α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991;32:1532-7.
176. 18F]fluoro-16 α-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 1994;21:941-52.
177. 18F] fluoroprogesterone: synthesis via halofluorination-oxidation, receptor binding and tissue distribution. Nucl Med Biol 1995;22:635-42.
178. Kochanny MJ, VanBrocklin HF, Kym PR, et al. Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J Med Chem 1993;36:1120-7.
179. Kym PR, Carlson KE, Katzenellenbogen JA. Progestin 16α, 17α-dioxolane ketals as molecular probes for the progesterone receptor: synthesis, binding affinity, and photochemical evaluation. J Med Chem 1993;36:1111-9.
180. Buckman BO, Bonasera TA, Kirschbaum KS, et al. Fluorine-18-labeled progestin 16α, 17α-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J Med Chem 1995;38:328-37.
181. 18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med 1991;32:81-8.
182. Pertschuk LP, Rosenthal HE, Macchia RJ. Correlation of histochemical an biochemical analysis of androgen binding in prostatic cancer: relation to therapeutic cancer. Cancer 1982;49:984-93.
183. Mobbs BG, Johnson IE. Basal and estrogen-stimulated hormone receptor profiles in four R3327 rat prostatic carcinoma sublines in relation to histopathology and androgen sensitivity. Cancer Res 1988;48:3077-83.
184. Ekman P, Snochowski M, Dahlberg E, et al. Steroid receptors in metastatic carcinoma of the human prostate. Eur J Cancer 1979;15:257-62.
185. Blankestein MA, Bolt-de-Vries J, van Aubel OGJM, et al. Hormone receptors in human prostate cancer. Scand. J Urol Nephrol 1988;Suppl 10:39-45.
186. Liu AJ, Dence CS, Welch MJ, et al. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-subsituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992;33:724-34.
187. Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 1996;37:1009-15.
188. Downer JB, Jones LA, Engelbach JA, et al. Comparison of animal models for the evaluation of radiolabeled androgens. Nucl Med Biol 2001;28:613-26.
189. Labaree DC, Hoyte RM, Nazareth LV, et al. 7α-iodo and 7α-fluoro steroids as androgen receptor mediated imaging agent. J Med Chem 1999;3:2021-34.
190. 18F]fluoro- 17[α]-methyl-5[α]-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol 2001;28:85-90.
191. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993;268:21513-8.
192. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
193. Hlatky L, Tsionou C, Hanhfeldt P, et al. Mammary fibroblasts may influence breast tumor angiogenesis, via hypoxia-induced vascular endothelial growth factor upregulation and protein expression. Cancer Res 1994;54:6083-6.
194. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
195. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 1987;84:9261-4.
196. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1986;83:5978-82.
197. Teicher BA. Physiologic mechanisms of therapeutic resistance. Hematol Oncol Clin North Am 1995;9:475-506.
198. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
199. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-8.
200. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
201. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10:695-712.
202. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983;43:1523-8.
203. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321-9.
204. Cater DB, Silver IA. Quantitative measurements of oxygen tension in normal tissues and in tumors of patients before and after radiotherapy. Acta Radiol 1960;53:233-56.
205. 2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 2002;41:304-12.
206. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
207. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol 1994;33:383-9.
208. Chapman JD, Schneider RF, Urbain JL, et al. Single photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol 2001;11:47-57.
209. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981;43:546-50.
210. Chapman JD. Hypoxic sensitizers: implications for radiation therapy. N Engl J Med 1979;301:1429-32.
211. Workman P Keynote. Bioreductive mechanisms. Int J Radiat Oncol Biol Phys 1992;22:631-7.
212. Chapman JD, Lee J, Meeker BE. Adduct formation by 2-nitroimidazole drugs in mammalian cells: optimization of markers for tissue oxygenation. In: Adams GE, Breccia A, Fielden EM, Wardman P, editors. Selective activation of drugs by redox processes. New York: Plenum; 1990. p. 313-23.
213. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983;43:1523-8.
214. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800.
215. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993;53:5721-6.
216. Raleigh JA, Miller GG, Franko AJ, et al. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer 1987;56:395-400.
217. 19F magnetic resonance method for measuring oxygen deficiency in tumors. Magn Reson Med 1991; 22:451-66.
218. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304.
219. Seddon BM, Maxwell RJ, Honess DJ, et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 2002;8:2323-35.
220. Hodgkiss RJ, Jones G, Long A, et al. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br J Cancer 1991;63:119-25.
221. Chapman JD, Engelhardt EL, Stobbe CC, et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-37.
222. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391-8.
223. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
224. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
225. Urtasun RC, McEwan AJ, Parliament MB, et al. Measurement of hypoxia in human tumors by SPECT imaging of iodoazomycin arabinoside. Br J Cancer 1996;74:209-12.
226. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90-5.
227. Grierson JR, Link JM, Mathis CA, et al. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-50.
228. Piert M, Machulla H, Becker G, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999;26:95-109.
229. 18F] fluoromisonidazole. Appl Radiat Isot 1993;44:1085-91.
230. 18F]fluoromisonidazole). Pharm. Res 1994;11:466-9.
231. Rasey JS, Koh WJ, Grierson JR, et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91.
232. Rasey JS, Nelson NJ, Chin L, et al. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301-8.
233. 3H]fluoromisonidazole. Radiat Res 1995;141:28-36.
234. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys 1995;22:1127-39.
235. Rasey JS, Casciari JJ, Hofstrand PD, et al. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84-92.
236. 18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700.
237. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
238. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-7.
239. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 1992;33:2202-8.
240. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378-83.
241. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704.
242. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391-8.
243. 18F]fluoro-2-deoxy- D-glucose. Acta Oncol 2000;39:629-37.
244. 18F]FETNIM: a potential marker for PET. J Nucl Med 2001;42:1397-404.
245. 18F]fluoroerythronitroimidazole PET. J Nucl Med 2001;42:1643-52.
246. 18F- fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 2002;43:1674-80.
247. 18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003;30:101-8.
248. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants to multiple-time uptake data. J Cereb Blood Flow Metab 1985;5:584-90.
249. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000; 27:661-70.
250. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072-9.
251. 18F]-EF1. Appl Radiat Isot 1999;51:643-50.
252. Evans SM, Joiner B, Jenkins WT, et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl) -N-(2,2,3,3,3-pentafluoropropyl) acetamidel. Br J Cancer 1995;72:875-82.
253. Evans SM, Jenkins WT, Joiner B, et al. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996;56:405-11.
254. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995;72:869-74.
255. 18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a nex fluorination procedure. Appl Radiat Isot 2001;54:73-80.
256. 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66.
257. 18F]EF1. J Nucl Med 2000;41:327-36.
258. 18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent. Biol Pharm Bull 2002; 25:616-21.
259. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962;3:332-4.
260. Galasko CSB. The pathological basis for skeletal scintigraphy. J Bone Joint Surg Br 1975;57:353-9.
261. 18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab 1993; 77:949-55.
262. Berger F, Lee YP, Loening AM, et al. Whole-body skeletal imaging in mice utilizing micro-PET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging 2002;29:1225-36.
263. Petren-Mallmin M. Clinical and experimental imaging of breast cancer metastases in the spine. Acta Radiol Suppl 1994;391:1-23.
264. 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998;27:72-6.
265. Schirrmeister H, Guhlmann A, Kotzerke J. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-9.
266. 18F PET. J Nucl Med 1999;40:1623-9.
267. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800-4.
268. Heidelberger C. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957;179:663-6.
269. Heidelberger C. Fluorinated pyrimidines. Prog Nucleic Acid Res Mol Biol 1965;4:1-50.
270. 18F-5-fluorouracil. Int J Appl Radiat Isot 1979; 30:401-5.
271. 18F-5-fluorouracil. VII. J Nucl Med 1973;14:63-4.
272. 18F-FU. Acta Radiol Oncol Radiat Phys Biol 1979;18:235-43.
273. 18F] fluorouracil in sensitive versus resistance lymphocytic leukemia in mice. Cancer Res 1977;37:2306-8.
274. 18F-5-fluorouracil in tumor-bearing mice and rats. Int J Nucl Med Biol 1978;5:19-28.
275. 18F-5- fluorouracil studies in humans and animals. Int J Radiat Oncol Biol Phys 1980;6:505-9.
276. 18F-fluorinating intermediate: trifluoromethyl hypoflurite. Int J Appl Radiat Isot 1978;29:323-7.
277. Visser GWM, Boele S, Van Halteren BW, et al. Mechanism and stereochemistry of the fluorination of uracil and cytosine using fluorine and acetyl hypofluorite. J Org Chem 1986;51:1466-71.
278. Visser GWM, Herder RE, De Kanter FJJ, et al. Fluorination of pyrimidines. Part 2. Mechanistic aspects of the reaction of acetyl hypofluorite with uracil and cytosine derivatives. J Chem Soc Perkin Trans I 1988;1203-7.
279. 18F-labelled-5-fluorouracil and a reevaluation of its use as a prognostic agent. Eur J Nuc Med 1989;15:225-9.
280. 18F]fluorouracil. J Label Compd Radiopharm 1999;42(Suppl 1):S533-5.
281. 18F-5-fluorouridine in rats. Eur J Nucl Med 1984;9:185-9.
282. 3H-deoxythymidine in tumor-bearing rats and mice. Eur J Nucl Med 1985; 10(1-2):39-44.
283. 18F-5-fluorouracil. Int J Nucl Med Biol 1982;9:25-35.
284. 18F-5-fluorouracil administered i.v. to rats bearing a mammary tumor. Int J Nucl Med Biol 1985;12:9-12.
285. Baker SD. Pharmacology of fluorinated pyrimidines: eniluracil. Invest New Drugs 2000;18:373-81.
286. 18F]fluorouracil pharmacokinetics. J Nucl Med 2000;41:1714-24.
287. 18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results. Nucl Med Biol 1996;23:333-42.
288. Young D, Vine E, Ghanbarpour A, et al. Metabolic and distribution studies with radiolabeled 5-fluorouracil. Nuklearmedizin 1982;21:1-7.
289. 18F]uracil positron emission tomography (PET). Eur J Cancer 1993;29A:1682-6.
290. 18F radioactivity in tumors. Onkologie 1989;12(Suppl 1):51-2.
291. Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993;34:1075-81.
292. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39:1197-202.
293. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997;57:3415-23.
294. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998;83:245-53.
295. Saleem A, Yap J, Osman S, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in vivo imaging of drug action. Lancet 2000;355:2125-31.
296. Aboagye EO, Saleem A, Cunningham VJ, et al. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001;61:4937-41.
297. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61-9.
298. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61:1781-5.
299. 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41-9.